10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“practice guidelines increasingly recognize the prevention of ischemic events as a key management priority.5,6”
In the citing paper
“However, subsequent trials that specifically examined the role of a blood pressure lowering strategy to <130 mm Hg in patients with T2DM and hypertension found no substantive benefit of intensive blood pressure control in reducing the risk of coronary events, although there was evidence for decreased risk of stroke.5,66–69”
In the citing paper
“As such, while all patients with T2DM and CAD certainly benefit from a blood pressure of <140/90 mm Hg,5,63–66,76”
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
In the citing paper
“Furthermore, fibrates or fish oil would be indicated when triglycerides are very high (>500 mg/dL) to reduce the risk of pancreatitis.5”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Research works printed but not linked: 2
- American College of Obstetricians and Gynecologists’, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Fitchett, 2017, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial, Eur Heart J, 39, 363, 10.1093/eurheartj/ehx511 · DOI · Paper page
Cited by
Items 301–400 of 470
Álvarez-Aliaga, A., Guerra, A. F., Quesada, A. S., Llano-Sosa, D. D., Saumell, J. B., & Santiesteban, Y. A. L. (2020) · Medwave · doi:10.5867/medwave.2020.03.7873 · Cited by 6
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2020) · PubMed Central · Cited by 5
Aspirin in primary prevention of cardiovascular disease in diabetes
Papazafiropoulou, A. K., Melidonis, A. J., & Antonopoulos, S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105596 · Cited by 5
Wang, D., Mu, S. Z., Tang, O., Echouffo-Tcheugui, J. B., MITCHELL, C. M., Fang, M., Rooney, M. R., Yeh, H. C., Rebholz, C. M., Pilla, S. J., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107845 · Cited by 4
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13637 · Cited by 4
Plazak, M. E., Mouradjian, M. T., Watson, K., Reed, B. N., Noel, Z. R., Devabhakthuni, S., & Gale, S. E. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1642108 · Cited by 4
Weng, W., Liang, Y. M., Brett, J., Hobbs, T. M., & Baeres, F. M. M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107500 · Cited by 5
NOD Mice Recapitulate the Cardiac Disturbances Observed in Type 1 Diabetes
Schleier, Y., Moreno-Loaiza, O., Alarcón, M. M. L., Martins, E. G. L., Braga, B. C., Ramos, I. P., Galina, A., & Medei, E. H. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10039-y · Cited by 5
Kao, Y.-C., Chen, T., Liu, C., Hwang, J., Hsiao, C.-C., Lin, Y., Mao, C., Hung, M., & Li, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86090-9 · Cited by 4
Guillén-Aguinaga, S., Forga, L., Brugos‐Larumbe, A., Guillén‐Grima, F., Guillén-Aguinaga, L., & Aguinaga-Ontoso, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245854 · Cited by 6
Kolasa, M., Olejnik, A., Rusak, E., & Chobot, A. P. (2022) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2022.122546 · Cited by 7
Bashir, A., Azharuddin, M., Rashid, I., Murti, K., & Pandey, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.012 · Cited by 5
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Huelgas, R. G., López, R. Q., Ramos, M. F. D., Serrado-Iglesias, A., Ruiz-Laiglesia, F., Franco, Á. G., Rodrigo, J. M. C., & Montero-Pérez-Barquero, M. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.008 · Cited by 3
Winter, W. E., Pittman, D. L., Devaraj, S., Li, D., & Harris, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818277-2.00008-x · Cited by 4
Wang, X., Liu, J., Huang, L., Zeng, H., He, G., Chen, L., Ma, R., Fu, W., & Ning, B. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029073 · Cited by 5
Troksa, K. A., Billups, S. J., Claus, L. W., Griend, J. P. V., & Saseen, J. J. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1222 · Cited by 5
Hitting the Sweet Spot: A Review of SGLT2i in Cardiovascular Medicine
Zayyad, Z. A., Gupta, N., Roy, A., Kalagara, S., Mishra, A., Salem, E., Seshadri, S. R., Gichi, D., Hammad, B., Ene, A., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00436-2 · Cited by 4
“In 2019, this recommendation was expanded to include both empagliflozin and canagliflozin, and a new C-level recommendation highlighted SGLTi as preferred for patients with ASCVD who were at high risk for HF or had coexisting HF [48].”
Yang, H., Qiao, Y., Lin, R., Yu, Y., Zhao, M., Magnussen, C. G., & Xi, B. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112948 · Cited by 3
Kazibwe, R., Singleton, M. J., Bancks, M. P., Namutebi, J. H., Hammoud, A., Shapiro, M. D., & Yeboah, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15753 · Cited by 5
“7 Similar recommendations are reflected in both the guidelines by the US Preventive Services Task Force 8 and the American College of Cardiology/American Heart Association, 9 and in those from the 2021 European Society of Cardiology guidelines on CVD prevention in clinical practice.”
Mlonga, J., & Damian, D. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/9966933 · Cited by 5
“Lifestyle modi fi - cations, including dietary interventions and exercise, play a fundamental role in managing dyslipidemia in T2DM, complemented by pharmacological interventions such as statins and fi brates to optimize lipid levels and mitigate cardiovascular risk [1].”
InfluentialHwang, Y., Kim, M. K., Park, J. H., Yun, H. M., Kim, S. Y., & Lim, S. K. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0146 · Cited by 6
Jyothi, C., Bandyopadhyay, D., Sahu, S., Patro, B. K., & Nayak, S. (2021) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00951-0 · Cited by 3
The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients
Fadah, K., Alashi, A., & Deoker, A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01619-8 · Cited by 4
Guo, X.-J., Wu, M., Pei, S., Xie, P., & Wu, M.-Y. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s351679 · Cited by 4
Hesary, F. B., Vahdaninia, V., Vahdaninya, Z., & Sadeghi, R. (2020) · Mudīrīyyat-i salāmat. · doi:10.29252/jha.23.3.66 · Cited by 3
Pulido‐Perez, P., Torres‐Rasgado, E., Pérez-Fuentes, R., Rosales‐Encina, J. L., Rodríguez‐Antolín, J., & Romero, J. R. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107974 · Cited by 3
Shkarin, V. V., Anfinogenova, O., Kochkonyan, T., Al‐Harazi, G., Kubanov, S. I., Domenyuk, S., Anfinogenov, V. A., Nuzhnaya, C., & Domenyuk, D. (2021) · Archiv Euromedica · doi:10.35630/2199-885x/2021/11/4.18 · Cited by 3
López, L. V., del Prado, P. S. C., Colin-Ramírez, E., Muñoz-Torres, A. V., & la Peña, J. E.-D. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.03.002 · Cited by 5
What does the NHS Long Term Plan mean for diabetes care?
Phillips, A. (2019) · Practice Nursing · doi:10.12968/pnur.2019.30.2.82 · Cited by 4
“…year after the programme, 86% were in diabetes remission, as were 57% of people who lost 10–15 kg and 34% who lost 5–10kg. Additionally, fat from the liver was also reduced using this low‑calorie approach, which further reduced cardiovascular risk factors (American Diabetes Association, 2019).”
BackgroundDiabetes e hipercolesterolemia familiar: un matrimonio peligroso
Gidding, S. S. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.01.008 · Cited by 4
Ward, R. C., Weeda, E. R., Bishu, K. G., Axon, R. N., Taber, D. J., & Gebregziabher, M. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1090 · Cited by 3
de León‐Ballesteros, G. P., Sánchez-Aguilar, H. A., Aguilar-Salinas, C. A., & Herrera, M. F. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05221-3 · Cited by 3
Гевко, У. П., & Марущак, М. І. (2021) · International Journal of Medicine and Medical Research · doi:10.11603/ijmmr.2413-6077.2020.2.11688 · Cited by 3
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.11.004 · Cited by 7
Stanojevic, V., Jevtić, M., Mitrović, M., Panajotovic, M., Aleksic, A., & Stanojević, Č. (2021) · Vojnosanitetski pregled · doi:10.2298/vsp211011104s · Cited by 2
Dayan, C. M., & Platts, J. K. (2020) · doi:10.1093/med/9780198746690.003.0259 · Cited by 3
Brandt, N., Johansen, M. L., Rasmussen, J., Dalsgaard, M., Kümler, T., Faber, J. O., Rossignol, P., Schou, M., & Kistorp, C. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03183-1 · Cited by 2
Filisa-Kaphamtengo, F., Ngoma, J., Mukhula, V. T., Matemvu, Z., Kapute, D., Banda, P., Phiri, T., Mipando, M., Hosseinipour, M. C., & Katundu, K. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03589-x · Cited by 2
“Dyslipi-daemia and DM increase the risk of ASCDs up to 2.4-fold in people living with HIV (PLWH) [19, 39–42].”
BackgroundInfluentialBasit, K. A., Fat, L. N., & Gregg, E. W. (2023) · Journal of Public Health · doi:10.1007/s10389-023-02143-5 · Cited by 3
Chihaoui, M., Terzi, A., Hammami, B., Oueslati, I., Khessairi, N., Chaker, F., Yazidi, M., & Feki, M. (2024) · Lipids · doi:10.1002/lipd.12399 · Cited by 2
Kamarullah, W., Pranata, R., Wiramihardja, S., & Tiksnadi, B. B. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00695-9 · Cited by 3
“…(e.g., hypertension, dyslipidemia) and without type 1 diabetes mellitus or T2DM (diabetes was defined as HbA1c levels of more than 6.5% [18]); (3) interventions were treatment with any and only one kind of incretin mimetics (controls had to be treated with placebo); and (4)…”
InfluentialZhang, F., & Zheng, H. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26009 · Cited by 4
Karlin, N. J., Buras, M. R., Kosiorek, H., Coppola, K., Verona, P. M., & Cook, C. B. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0055 · Cited by 2
Busch, N., Jensen, M. T., Goetze, J. P., Schou, M., Biering‐Sørensen, T., Fritz‐Hansen, T., Andersen, H. U., Vilsbøll, T., Rossing, P. R., & Jørgensen, P. G. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13172 · Cited by 3
Brunton (2021) · The Journal of Family Practice · doi:10.12788/jfp.0290 · Cited by 4
Xia, T., Yang, Y., Li, W., Tang, Z., Li, Z., & Guo, Y. (2019) · Medicine · doi:10.1097/md.0000000000015639 · Cited by 3
Zhou, L., Cai, X., Luo, Y., Zhang, F., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9347132 · Cited by 2
Uncommon Presentations of Diabetes: Zebras in the Herd
Shidler, K. L., Letourneau, L. R., & Novak, L. M. (2019) · Clinical Diabetes · doi:10.2337/cd19-0019 · Cited by 4
Blood Pressure and Hypertension Management
Norris, K. C., & Beech, B. M. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_11 · Cited by 2
La importancia del control de la dislipemia en el paciente con diabetes mellitus tipo 2
Carrasco-Sánchez, F. J. (2021) · doi:10.52102/control_dislipemia/art-1 · Cited by 4
Konstantonis, G. D., Arida, A., Aissopou, E. K., Protogerou, A. D., Tentolouris, N., Sfikakis, P. P., & Makrilakis, K. (2021) · Angiology · doi:10.1177/00033197211010622 · Cited by 2
Gómez, M., Ramírez, T., & Escobar-Salinas, J. S. (2021) · Revista científica ciencias de la salud · doi:10.53732/rccsalud/03.02.2021.03 · Cited by 2
Predictors of health-related quality of life among Iranian people with type 2 diabetes
Alamdari, M., Sajad, R. S., & Salehidoost, R. (2022) · Journal of Nephropharmacology · doi:10.34172/npj.2022.10501 · Cited by 1
Pacileo, G., Morando, V., Banks, H., Ferrara, L., Cattelan, A. M., Luzzati, R., Manfrin, V., & Tozzi, V. D. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac120 · Cited by 3
Peták, F., Kovács, B. N., Agócs, S., Virág, K., Nyári, T., Molnár, A., Südy, R., Lengyel, C., & Babik, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274105 · Cited by 2
Abtan, J., Bhatt, D. L., Elbez, Y., Ducrocq, G., Goto, S., Smith, S. C., Ohman, E. M., Eagle, K. A., Fox, K. M., Harrington, R. A., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.132 · Cited by 2
Ertugliflozin in type 2 diabetes: a profile of its use
Scott, L. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00651-7 · Cited by 2
Diabetes and familial hypercholesterolemia: an unhealthy marriage
Gidding, S. S. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.01.002 · Cited by 3
Marx, N., Rydén, L., Brosius, F. C., Ceriello, A., Cheung, M., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0086 · Cited by 2
Цукровий діабет і хронічний коронарний синдром
Serhiyenko, V. A., & Serhiyenko, A. A. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.1.2021.226431 · Cited by 2
Type-2 diabetes with low LDL-C: genetic insights into a unique phenotypePreprint
Klimentidis, Y. C., Arora, A., Newell, M., Zhou, J. J., Ordovás, J. M., Renquist, B. J., & Wood, A. C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/837013 · Cited by 2
Wongcharoen, W., Osataphan, N., Prasertwitayakij, N., Suwannasom, P., Suraamornkul, S., Wongtheptian, W., Gunaparn, S., Sirikul, W., & Phrommintikul, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-41864-1 · Cited by 2
Lundholm, M. D. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112682 · Cited by 1
Nocturnal Hypertension and Nondipping Blood Pressure: Nature or Nurture?
Ferdinand, K. C., & Sweeney, A. W. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz056 · Cited by 2
Translating Evidence From Clinical Trials of omega-3 Fatty Acids to Clinical Practice
Nelson, A. J., & Nicholls, S. J. (2020) · Future Cardiology · doi:10.2217/fca-2019-0031 · Cited by 1
Roy, S., Bhattacharya, G., & Bera, M. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00299-9 · Cited by 2
Kellick, K. A., & Saseen, J. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_11 · Cited by 2
Zeng, T., Yuan, H., Ren, J., Li, Y., Hou, J., Du, L., Zhu, J., Chen, L., & Ji, L. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01007-z · Cited by 2
Diabetes Mellitus and Chronic Kidney Disease (Stages 1–5)
Elger, M., Parpia, A. S., & Whitham, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-44858-5_11 · Cited by 1
Su, S., & Yeh, W.-T. (2023) · Asian Nursing Research · doi:10.1016/j.anr.2023.02.001 · Cited by 3
Hamayal, M., Akhtar, C. H., Ahmad, N., Awwab, M., Shahid, W., Abbasi, H. S., Nadeem, E., Siddiqui, E., Zafar, W., & Hussain, S. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00727-y · Cited by 1
Blutdruckziele bei Patienten mit Diabetes mellitus: Was sind optimale Werte?
Dederer, J., Bewarder, Y., Mahfoud, F., & Böhm, M. (2019) · Herz · doi:10.1007/s00059-019-4796-5 · Cited by 1
Mehdiyev, S. K., Мустафаев, И. И., & Мамедов, М. Н. (2019) · Kardiologiia · doi:10.18087/cardio.2019.9.10271 · Cited by 1
Defining the Role of Icosapent Ethyl in Clinical Practice
Chatterjee, S., Hajra, A., Bandyopadhyay, D., Ghosh, R. K., & DEEDWANIA, P. C. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00402-4 · Cited by 1
Ena, J., Carretero‐Gómez, J., Zapatero, A., Carrasco-Sánchez, F. J., Romero-Sánchez, M., González-Becerra, C., Blázquez-Encinar, J. C., Igúzquiza-Pellejero, M. J., Yangüela, B. D. E., & Gómez‐Huelgas, R. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.12.015 · Cited by 1
Nashawi, M., Sheikh, O., Mir, M., Te, T., & CHILTON, R. J. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000204 · Cited by 1
Koziolova, N. A., Karavaev, P. G., & Veklich, A. S. (2020) · Kardiologiia · doi:10.18087/cardio.2020.4.n1042 · Cited by 1
Rodríguez‐Martín, S., García‐Lledó, A., Gil, M., Barreira‐Hernández, D., Rodríguez-Miguel, A., & de Abajo, F. J. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.10.008 · Cited by 2
Siddiqui, N. A., Akhtar, N., Shahid, A., Taj, F. B., Ayaz, A., Moosa, Z. A., & Azeem, F. (2020) · ANNALS OF ABBASI SHAHEED HOSPITAL AND KARACHI MEDICAL & DENTAL COLLEGE · doi:10.58397/ashkmdc.v25i2.326 · Cited by 1
Treatment of Diabetes and Heart Failure
Brochu, B., & Chan, M. C. Y. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_53 · Cited by 1
ОСОБЛИВОСТІ КОМОРБІДНОГО ПЕРЕБІГУ ЦУКРОВОГО ДІАБЕТУ 2 ТИПУ ТА ГІПОТИРЕОЗУ: ЛАБОРАТОРНІ ДАНІ
Musiienko, V., & Марущак, М. І. (2021) · Medical and Clinical Chemistry · doi:10.11603/mcch.2410-681x.2021.i3.12448 · Cited by 1
Asmar, N. E., Arafah, B. M., & Smith, C. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_186 · Cited by 1
Savji, N., & Berger, J. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_13 · Cited by 1
Lin, S.-Y., Lin, C., Lin, C., Hsu, W.-H., Hsu, C. Y., & Kao, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.786203 · Cited by 1
“DCCBs have been effective in lowering systolic blood pressure to <130 mmHg in different patient populations in combination with other antihypertensives (Haller, 2008; Matsui et al., 2009; Association, 2019).”
BackgroundCardiovascular disease in type 1 diabetes: the elephant in the clinic
Petrie, J. R. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000170 · Cited by 1
Echouffo-Tcheugui, J. B., & Kengne, A. P. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz515 · Cited by 1
Macrovascular Disease in Type 1 Diabetes
Petrie, J. R. (2022) · doi:10.1093/med/9780198870197.003.0281 · Cited by 2
New therapies for diabetes mellitus
Barbieri, M., Cataldo, V., Griffing, G. T., & Paolisso, G. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch87 · Cited by 1
Katundu, K., Mukhula, V. T., Matemvu, Z., Mtonga, A. J., Ndambo, M. K., Lubanga, A. F., Malenje, M. G., Nyangulu, W., Momba, G., Triulzi, I., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5373585/v1 · Cited by 4
“People living with HIV (PLWH) have an increased risk of ASCDs, and the presence of hypertension, dyslipidaemia or DM increases the risk of ASCD up to 2.4-fold in PLWH [4–11].”
InfluentialFerraro, R., NASS, C. M., Dudum, R., Blumenthal, R. S., & Sarkar, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.02.050 · Cited by 1
The Management of Hypertension in People With Diabetes
Bucheit, J. D., & Sisson, E. M. (2019) · AADE in Practice · doi:10.1177/2325160319843370
Education of Patients with Diabetes Mellitus and Peripheral Artery Disease
Yun, H. R. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.2.99
Welche Zielwerte sind bei Typ-2-Diabetes relevant?
Jacob, S. (2019) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-019-1058-7
Valle, J. A., & Ho, P. M. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.014704
Fasanella, D. R. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.pregnancy_overview
Leçons des grandes études cardiovasculaires et rénales portant sur les nouveaux antidiabétiques
Halimi, S. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30960-7
Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients
Yu, S. H. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.4.233
Kayingo, G., & Hass, V. M. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.12.002
Writers, A. M. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00714-0
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S103-S123
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4213222556
- Semantic Scholar
- b0a37d21ada65be89484f4b750bf45f281a7f7c5
- Cited by
- 471
- References
- 172
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 20 · 2023: 35 · 2022: 65 · 2021: 84 · 2020: 134 · 2019: 109
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care, treatment goals, level of evidence
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Risk Management, Societies, Medical, United States, Practice Guidelines as Topic, Diabetic Cardiomyopathies, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.